Soligenix, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNGX research report →
Price Chart
About the company
Soligenix, Inc. , a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions.
- CEO
- Christopher J. Schaber
- IPO
- 1994
- Employees
- 14
- HQ
- Princeton, NJ, US
Get TickerSpark's AI analysis on SNGX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.14M
- P/E
- -0.32
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.85
- EV/EBITDA
- 0.32
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -165.88%
- ROIC
- -142.45%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-11,845,476
- Net Income
- $-11,080,380-34.0%
- EPS
- $-2.14+57.0%
- OCF Growth
- -22.2%
- FCF Growth
- -22.2%
- 52W High
- $1.70
- 52W Low
- $0.21
- 50D MA
- $0.35
- 200D MA
- $0.61
- Beta
- 2.04
- RSI (14)
- 17
- Avg Volume
- 208.44K
No earnings-call transcripts are available for SNGX yet.
- Free Float
- 95.4%
- Shares Outstanding
- 23.37M
- Float Shares
- 22.30M
of shares held by institutions
15 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Citadel Advisors LLC | 209.51K | ▲ 209.51K |
| Xtx Topco Ltd | 157.12K | ▲ 136.32K |
| Geode Capital Management, LLC | 105.62K | ▼ 14.65K |
| Vanguard Group Inc | 85.47K | ▲ 32.95K |
| Vanguard Capital Management LLC | 81.00K | 0 |
| Jane Street Group, LLC | 62.71K | ▼ 144.78K |
| Virtu Financial LLC | 60.90K | ▲ 60.90K |
| Stonex Group Inc. | 56.71K | ▲ 56.71K |
| Vanguard Fiduciary Trust Co | 53.91K | 0 |
| Renaissance Technologies LLC | 44.90K | ▲ 44.90K |
| Northern Trust Corp | 38.05K | ▲ 38.05K |
| Citigroup Inc | 9.96K | ▲ 9.96K |
Held by 6 ETFs
Biggest fund positions in SNGX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 12, 26 | ZELDIS JEROME B | sell | 54 |
| Oct 12, 26 | ZELDIS JEROME B | sell | 74 |
| Oct 12, 26 | ZELDIS JEROME B | sell | 128 |
| Oct 12, 26 | ZELDIS JEROME B | sell | 63 |
| Oct 12, 26 | ZELDIS JEROME B | sell | 121 |
| Oct 12, 26 | ZELDIS JEROME B | sell | 192 |
| Oct 12, 26 | RUBIN ROBERT J. | sell | 54 |
| Oct 12, 26 | RUBIN ROBERT J. | sell | 74 |
| Oct 12, 26 | RUBIN ROBERT J. | sell | 128 |
| Oct 12, 26 | RUBIN ROBERT J. | sell | 63 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SNGX coverage
Recent articles, reports, and earnings notes.
No research on SNGX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SNGX report →Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results
prnewswire.com · Nov 6
Contrasting Zura Bio (NASDAQ:ZURA) and Soligenix (NASDAQ:SNGX)
defenseworld.net · Aug 27
Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results
prnewswire.com · Aug 7
From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak
feeds.newsfilecorp.com · Jun 26
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
prnewswire.com · Jun 8
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
prnewswire.com · May 26
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
prnewswire.com · May 8
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
prnewswire.com · Apr 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.